Recombinant DNA Technology Market Growth, Demand and Challenges of the Key Industry Players 2023-28 - PowerPoint PPT Presentation

About This Presentation
Title:

Recombinant DNA Technology Market Growth, Demand and Challenges of the Key Industry Players 2023-28

Description:

According to the latest research report by IMARC Group, The global recombinant DNA technology market size reached US$ 729.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 966.8 Billion by 2028, exhibiting a growth rate (CAGR) of 4.7% during 2023-2028. More Info:- – PowerPoint PPT presentation

Number of Views:1
Slides: 14
Provided by: MarcelMikaelson
Category:
Tags:

less

Transcript and Presenter's Notes

Title: Recombinant DNA Technology Market Growth, Demand and Challenges of the Key Industry Players 2023-28


1
Global Recombinant DNA Technology Market Research
and Forecast Report 2023-2028
  • Format PDFEXCEL

2023 IMARC All Rights Reserved
2
About IMARC Group
  • International Market Analysis Research and
    Consulting Group is a leading adviser on
    management strategy and market research
    worldwide. We partner with clients in all regions
    and industry verticals to identify their
    highest-value opportunities, address their most
    critical challenges, and transform their
    businesses.
  • IMARCs information products include major
    market, scientific, economic and technological
    developments for business leaders in
    pharmaceutical, industrial, and high technology
    organizations. Market forecasts and industry
    analysis for biotechnology, advanced materials,
    chemicals, food and beverage, travel and tourism,
    nanotechnology and novel processing methods are
    at the top of the companys expertise.
  • IMARCs tailored approach combines unfathomable
    insight into the dynamics of companies and
    markets with close cooperation at all levels of
    the client organization. This ensures that our
    clients achieve unmatchable competitive
    advantage, build more proficient organizations,
    and secure lasting results.

3
Report Highlight and Description
  • According to the latest report by IMARC Group,
    titled "Recombinant DNA Technology Market Global
    Industry Trends, Share, Size, Growth, Opportunity
    and Forecast 2023-2028," the global recombinant
    DNA technology market size reached US 729.8
    Billion in 2022.
  • Recombinant deoxyribonucleic acid (DNA)
    technology refers to the process of altering
    genetic materials to obtain desired
    characteristics in living organisms or their
    products. It involves multiple steps, such as
    isolation of genetic material, restriction enzyme
    digestion, amplification using polymerase chain
    reaction (PCR), ligation of DNA molecules, and
    insertion of recombinant DNA into the host.
  • It is widely used in manufacturing
    pharmaceuticals, novel enzymes for food
    processing, production of genetically modified
    organisms (GMO), gene therapy, and clinical
    diagnosis. Recombinant DNA technology is vital in
    improving health, enhancing food resources, and
    solving environmental problems. It also aids in
    the production of vaccines and protein therapies
    such as human insulin, interferon, and human
    growth hormone.
  • Request for a PDF sample of this report
    https//www.imarcgroup.com/recombinant-dna-technol
    ogy-market/requestsample

4
Report Description
  • Global Recombinant DNA Technology Market Trends
  • The global recombinant DNA technology market is
    primarily being driven by its increasing
    utilization in the pharmaceutical industry.
    Recombinant DNA technology is extensively used in
    developing vaccines and manufacturing insulin,
    human growth hormones, antibiotics, and
    monoclonal antibodies. In addition, the
    widespread adoption of gene therapy in the
    healthcare industry to treat cancer,
    cardiovascular diseases (CVDs), infertility, and
    genetic diseases is acting as another
    growth-inducing factor. Furthermore, the
    increasing demand for recombinant DNA technology
    in the agriculture industry to develop GMO crops
    with better yield, microbial resistance, drought
    resistance, salt tolerance, and high nutrition
    levels is providing an impetus to the market
    growth. Additionally, the introduction of new
    technologies, such as Clustered regularly
    interspaced short palindromic repeats (CRISPR or
    Cas9), Zinc-finger nucleases (ZFNs), and
    transcription activator-like effector nucleases
    (TALENs) for simple, cost-effective, and precise
    genome editing is creating a positive outlook for
    the market. Other factors, including increasing
    demand for recombinant DNA technology for
    improving different health conditions, extensive
    research and development (RD) activities in
    novel therapeutics, and widespread utilization in
    the production of transgenic animals, are
    anticipated to drive the market growth.
  • Looking forward, the market is expected to reach
    US 966.8 Billion by 2028, exhibiting a CAGR of
    4.7 during 2023-2028.
  • View Report TOC, Figures and Tables
    https//www.imarcgroup.com/recombinant-dna-technol
    ogy-market

5
Report Segmentation
  • Breakup by Product
  • Medical
  • Therapeutic Agent
  • Human Protein
  • Vaccines
  • Non-Medical
  • Biotech Crops
  • Specialty Chemicals
  • Others
  •  
  • Breakup by Component
  • Expression System
  • Cloning Vector
  • Breakup by Application
  • Food and Agriculture

6
Report Segmentation
  • Health and Disease
  • Environment
  • Others
  • Breakup by End User
  • Biotechnology and Pharmaceutical Companies
  • Academic and Government Research Institutes
  • Others
  • Breakup by Region
  • North America
  • Asia-Pacific
  • Europe
  • Latin America
  • Middle East and Africa

7
Competitive Landscape with Key Players
  • Amgen Inc
  • Cibus
  • F.Hoffmann-La Roche Ltd
  • GenScript
  • GlaxoSmithKline plc.
  • Horizon Discovery Group plc
  • Merck KGaA
  • New England Biolabs
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi S.A
  • Syngene International Ltd (Biocon Limited).

8
Key Questions Answered in the Report
9
Key Questions Answered in the Report
10
Table of Contents
  • 1    Preface2    Scope and Methodology    2.1  
     Objectives of the Study    2.2  
     Stakeholders    2.3    Data Sources       
    2.3.1    Primary Sources        2.3.2  
     Secondary Sources    2.4    Market Estimation 
          2.4.1    Bottom-Up Approach        2.4.2  
     Top-Down Approach    2.5    Forecasting
    Methodology3    Executive Summary4  
     Introduction    4.1    Overview    4.2    Key
    Industry Trends5    Global Recombinant DNA
    Technology Market    5.1    Market Overview   
    5.2    Market Performance    5.3    Impact of
    COVID-19  5.4    Market Forecast
  • 6     Market Breakup by Product    6.1  
     Medical        6.1.1 Market Trends       
    6.1.2 Key Segments           6.1.2.1 Therapeutic
    Agent           6.1.2.2 Human Protein         
     6.1.2.3 Vaccines        6.1.3 Market Forecast 
      6.2    Non-Medical        6.2.1 Market
    Trends        6.2.2 Key Segments       

11
Table of Contents
  •            6.2.2.1 Biotech Crops         
     6.2.2.2 Specialty Chemicals           6.2.2.3
    Others        6.2.3 Market Forecast7   Market
    Breakup by Component    7.1    Expression
    System        7.1.1 Market Trends        7.1.2
    Market Forecast    7.2    Cloning Vector       
    7.2.1 Market Trends        7.2.2 Market
    Forecast8   Market Breakup by Application   
    8.1    Food and Agriculture        8.1.1 Market
    Trends        8.1.2 Market Forecast    8.2  
     Health and Disease        8.2.1 Market Trends 
          8.2.2 Market Forecast    8.3  
     Environment        8.3.1 Market Trends       
    8.3.2 Market Forecast    8.4    Others       
    8.4.1 Market Trends        8.4.2 Market Forecast
  • 9   Market Breakup by End User    9.1  
     Biotechnology and Pharmaceutical Companies     
      9.1.1 Market Trends        9.1.2 Market
    Forecast
  • For more information, visit https//www.imarcgrou
    p.com/recombinant-dna-technology-market/toc

12
Disclaimer
  • 2023 IMARC All Rights Reserved
  • This Publication and all its contents unless
    otherwise mentioned are copyrighted in the name
    of International Market Analysis Research and
    Consulting (IMARC). No part of this publication
    may be reproduced, repackaged, redistributed or
    resold in whole or in any part. The publication
    may also not be used in any form or by and means
    graphic electronic or mechanical, including
    photocopying, recording, taping or by information
    storage or retrieval, or by any other form,
    without the express consent of International
    Market Analysis Research and Consulting (IMARC).
  • Disclaimer All contents and data of this
    publication, including forecasts, data analysis
    and opinion have been based on information and
    sources believed to be accurate and reliable at
    the time of publishing. International Market
    Analysis Research and Consulting makes no
    representation of warranty of any kind as to the
    accuracy or completeness of any Information
    provided. IMARC accepts no liability whatsoever
    for any loss or damage resulting from opinion,
    errors or inaccuracies if any found this
    publication.
  • IMARC, IMARC Group and Global Therapy Insight
    Series are registered trademarks of International
    Market Analysis Research and Consulting. All
    other trademarks used in this publication are
    registered trademarks of their respective
    companies.

13
Contact Us
Visit us at
https//www.imarcgroup.com
TELEPHONE 1-631-791-1145 E-MAIL
sales_at_imarcgroup.com
Write a Comment
User Comments (0)
About PowerShow.com